Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection

Journal of Renal Care

Volumn 37, Issue 1, 2011, Pages 25-29

  Aperis, Georgios ^a   Paliouras, Christos ^a   Zervos, Angelos ^a   Arvanitis, Antonios ^a   Alivanis, Polichronis ^a  

^a General Hospital of Rhodes   (Greece)

Author keywords

Diabetes mellitus; HIV AIDS; Lactic acidosis; Metformin; Slow continuous haemofiltration; Tenofovir

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDIABETIC AGENT; DRUG DERIVATIVE; METFORMIN; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACIDOSIS, LACTIC; ACUTE KIDNEY INJURY; ADENINE; AGED; ANTI-HIV AGENTS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79551523299     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2011.00209.x     Document Type: Article

References (29)

1. Alivanis P., Giannikouris I. & Paliuras C. (2006). Metformin-associated lactic acidosis treated with continuous renal replacement therapy. Clinical Therapeutics 28, 396-400.
2. Atta M.G. & Fine D.M. (2009). Editorial comment: tenofovir nephrotoxicity-the disconnect between clinical trials and real-world practice. AIDS Reader 19, 118-119.
3. Birkus G., Hitchcock M.J. & Cihlar T. (2002). Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrobial Agents Chemotherapy 46, 716-723.
4. Bodmer M., Meier C. & Krahenbuhl S. (2008). Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 31, 2086-2091.
5. Bpharm S.M., Talbot A. & Trottier B. (2008). Acute renal failure in four HIV-infected patients: Potential association with tenofovir and nonsteroidal anti-inflammatory drugs. The Canadian Journal of Infectious Diseases & Medical Microbiology 19, 75-76.
6. Chang C.T., Chen Y.C. & Fang J. T. (2002). Metformin-associated lactic acidosis: case reports and literature review. Journal of Nephrology 15, 398-402.
7. Dupont C., Meier F. & Loupy A. (2003). Acute renal failure and tenofovir: two new cases. Antiviral Therapy 8(Suppl 1), Abstract no. 694.
8. Fauci A.S. & Lane C.H. (2008). Human immunodeficiency virus disease: AIDS and related disorders. In Harrison's Principles of Internal Medicine (eds Fauci A. S., Braunwald E., Kasper D. L. et al.), Volume I, 17th edn, pp. 1137-1204. New York McGraw Hill.
9. Fisman E.Z. & Tenenbaum A. (2009). A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8, 38.
10. Gilead Sciences Inc. Viread (Tenofovir) Product Monograph. 2001. (accessed 1 April 2010).
11. Hann H.W., Chae H.B. & Dunn S.R. (2008). Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatology International 2, 244-249.
12. Kapitsinou P.P. & Ansari N. (2008). Acute renal failure in an AIDS patient on tenofovir: a case report. Journal of Medical Case Reports 2, 94.
13. Karras A., Lafaurie M. & Furco A. (2003). Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clinical Infectious Disease 36, 1070-1073.
14. Kearney B.P., Yale K. & Shah J. (2006). Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clinical Pharmacokinetics 45, 1115-1124.
15. Kohler J.J., Hosseini S.H. & Hoying-Brandt A. (2009). Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Laboratory Investigation 89, 513-519.
16. Lalau J.D. & Race J.M. (1999). Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Safety 20, 377-384.
17. Morelle J., Labriola L. & Lambert M. (2009). Tenofovir-related acute kidney injury and proximal tubule dysfunction precipitated by diclofenac: a case of drug-drug interaction. Clinical Nephrology 71, 567-570.
18. Nurutdinova D. & Overton T. (2007). Human immunodeficiency virus infection and acquired immunodeficiency syndrome. In The Washington Manual of Medical Therapeutics (eds Cooper D. H., Krainik A. J. & Lubner S. J.), 32nd edn, pp. 408-417. New York Wolters Kluwer Lippincott Williams & Wilkins.
19. Peters N., Jay N. & Barraud D. (2008). Metformin-associated lactic acidosis in an intensive care unit. Critical Care 12, R149.
20. Peyriere H., Reynes J. & Rouanet I. (2004). Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. Journal of Acquired Immune Deficiency Syndromes 35, 269-273.
21. Psevodos G. Jr., Gonzales E. & Sharp V. (2009). Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Reader 19, 245-248.
22. Ray A.S., Cihlar T. & Robinson K.L. (2006). Mechanism of active renal tubular efflux of tenofovir. Antimicrobial Agents and Chemotherapy 50, 3297-3304.
23. Rivas P., Polo J. & de Gorgolas M. (2003). Drug points: Fatal lactic acidosis associated with tenofovir. BMJ 327, 711.
24. Rodriguez-Novoa S., Labarga P. & Soriano V. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clinical Infectious Disease 48, e108-e116.
25. Skowron G., Bratberg J. & Pauwels R. (2006). Emtricitabine. In Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (eds Skowron G. & Ogden R), 1st edn, pp. 133-157. Totowa Humana Press.
26. Stumvoll M., Nurjhan N. & Perriello G. (1995). Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. The New England Journal of Medicine 333, 550-554.
27. Uwai Y., Ida H. & Tsuji Y. (2007). Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharmaceutical Research 24, 811-815.
28. Verhelst D., Monge M. & Meynard J.L. (2002). Fanconi syndrome and renal failure induced by tenofovir: a first case report. American Journal of Kidney Diseases 40, 1331-1333.
29. Zimmermann A.E., Pizzoferrato T., Bedford J. et al. (2006). Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Disease 42(2), 283-290.